Answers are grounded in this paper and cite their sources.
Microangiopathic hemolytic anemia and thrombocytopenia should be recognized as a potential complication in patients with congenital heart disease and pulmonary hypertension.
Microangiopathic hemolytic anemia and thrombocytopenia have been reported in patients with primary pulmonary hypertension, but not in patients with congenital heart disease even if accompanied with pulmonary hypertension. We present a 7-year-old boy with atrial septal defect and pulmonary hypertension who developed microangiopathic hemolysis and thrombocytopenia. Microangiopathic hemolytic anemia and thrombocytopenia should be remarked as a complication in patients with congenital heart disease.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: